Acquisition Interest LumiThera has prominent signals of potential acquisition by Alcon in 2025, indicating a strategic buyer landscape. Engage as a sales development professional by aligning messaging to demonstrate how Valeda and PBM capabilities complement Alcon’s retina portfolio and speed to market for dry AMD therapies.

dry AMD Focus The company specializes in dry age-related macular degeneration with multiwavelength PBM via Valeda, and has ongoing topline data releases. Explore opportunities to position broader payer access, clinical adoption programs, and bundled offerings with imaging/diagnostics to expand physician adoption in ophthalmology networks.

Regulatory & Coding Category III CPT code established for 2025 signals reimbursement progress and payer engagement. Build sales plays around coding clarity, value propositions for clinicians, and pathways for hospital systems to bill photobiomodulation treatments efficiently.

Clinical Validation Active clinical registry and safety/efficacy studies indicate demand for real-world data. Propose partnerships for multi-center trials, post-market real-world evidence collaborations, and data-sharing agreements to strengthen adoption among retinal specialists.

Global Expansion Products are FDA authorized and CE marked with select international availability, plus European registry studies. Target international distributors and ophthalmology networks, emphasizing regulatory readiness, local reimbursement insights, and training programs to accelerate geographic rollout.